Ginkgo Bioworks Holdings (DNA) Payables (2020 - 2026)

Ginkgo Bioworks Holdings has reported Payables for 7 years, with the latest figure at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 44.75% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 44.75% YoY), and the FY2025 full-year result was $10.6 million, down 25.43% from the prior year.
• Payables for Q1 2026 stood at $16.3 million, up from $10.6 million in the prior quarter.
• The five-year high for Payables was $35.3 million in Q1 2022, with the low at $9.3 million in Q4 2023.
• Historically, Payables has averaged $16.0 million across 5 years, with a median of $13.6 million in 2023.
• Annual changes were most pronounced in 2022 — Payables surged 2379.71% — and 2025, when it plunged 58.26%.
• Ginkgo Bioworks Holdings' Payables stood at $10.5 million in 2022, then dropped by 10.79% to $9.3 million in 2023, then soared by 51.98% to $14.2 million in 2024, then fell by 25.43% to $10.6 million in 2025, then surged by 54.35% to $16.3 million in 2026.
• The last three Payables figures came in at $16.3 million (Q1 2026), $10.6 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.